Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 13;28(24):8068.
doi: 10.3390/molecules28248068.

Investigation of Drug-Interaction Potential for Arthritis Dietary Supplements: Chondroitin Sulfate, Glucosamine, and Methylsulfonylmethane

Su Min Kim  1 , So Young Jo  1 , Ho-Young Park  2 , Yu Ra Lee  2 , Jun Sang Yu  1 , Hye Hyun Yoo  1
Affiliations

Investigation of Drug-Interaction Potential for Arthritis Dietary Supplements: Chondroitin Sulfate, Glucosamine, and Methylsulfonylmethane

Su Min Kim et al. Molecules. .

Abstract

Osteoarthritis is one of the leading conditions that promote the consumption of these dietary supplements. Chondroitin sulfate, glucosamine, and methylsulfonylmethane are among the prominent alternative treatments for osteoarthritis. In this study, these dietary supplements were incubated with cytochrome P450 isozyme-specific substrates in human liver microsomes, and the formation of marker metabolites was measured to investigate their inhibitory potential on cytochrome P450 enzyme activities. The results revealed no significant inhibitory effects on seven CYPs, consistent with established related research data. Therefore, these substances are anticipated to have a low potential for cytochrome P450-mediated drug interactions with osteoarthritis medications that are likely to be co-administered. However, given the previous reports of interaction cases involving glucosamine, caution is advised regarding dietary supplement-drug interactions.

Keywords: chondroitin sulfate; cytochrome P450; glucosamine; methylsulfonylmethane; osteoarthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Representative analysis chromatograms of probe metabolites in control and CS (100 μM), GCS (300 μM), and MSM (300 μM)-treated samples. Arrows show peak of probe metabolites.
See this image and copyright information in PMC

References

    1. Persiani S., Canciani L., Larger P., Rotini R., Trisolino G., Antonioli D., Rovati L.C. In vitro study of the inhibition and induction of human cytochromes P450 by crystalline glucosamine sulfate. Drug Metab. Drug Interact. 2009;24:195–209. doi: 10.1515/DMDI.2009.24.2-4.195. - DOI - PubMed
    1. Liu X., Machado G.C., Eyles J.P., Ravi V., Hunter D.J. Dietary supplements for treating osteoarthritis: A systematic review and meta-analysis. Br. J. Sports Med. 2018;52:167–175. doi: 10.1136/bjsports-2016-097333. - DOI - PubMed
    1. Neogi T., Zhang Y.Q. Epidemiology of Osteoarthritis. Clin. Geriatr. Med. 2013;39:355–369. doi: 10.1016/j.rdc.2012.10.004. - DOI - PMC - PubMed
    1. Primorac D., Molnar V., Matisic V., Hudetz D., Jelec Z., Rod E., Cukelj F., Vidovic D., Vrdoljak T., Dobricic B., et al. Comprehensive Review of Knee Osteoarthritis Pharmacological Treatment and the Latest Professional Societies’ Guidelines. Pharmaceuticals. 2021;14:205. doi: 10.3390/ph14030205. - DOI - PMC - PubMed
    1. da Costa B.R., Reichenbach S., Keller N., Nartey L., Wandel S., Jüni P., Trelle S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: A network meta-analysis. Lancet. 2016;387:2093–2105. doi: 10.1016/S0140-6736(16)30002-2. - DOI - PubMed